

# Gopakumar V Iyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4834298/publications.pdf>

Version: 2024-02-01

100  
papers

14,536  
citations

87888

38  
h-index

42399

92  
g-index

107  
all docs

107  
docs citations

107  
times ranked

21312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic therapy in bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 39-47.	1.6	8
2	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. <i>BJU International</i> , 2022, 129, 463-469.	2.5	9
3	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	1.6	42
4	Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. <i>Scientific Reports</i> , 2022, 12, 974.	3.3	8
5	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	12.8	37
6	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 431-441.	1.9	5
7	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6
8	Lessons from the Study of Exceptional Responders. <i>Cancer Cell</i> , 2021, 39, 11-13.	16.8	26
9	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1997-2010.	7.0	15
10	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.07.016">https://doi.org/10.1016/j.eururo.2020.07.016</a> . <i>European Urology</i> , 2021, 79, e56-e57.	1.9	0
11	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2011-2022.	7.0	19
12	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	7.0	25
13	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
14	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 430-438.	0.7	14
15	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	8.2	26
16	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	1.9	2
17	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
18	Developing Precision Medicine for Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 633-653.	2.2	9

#	ARTICLE	IF	CITATIONS
19	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 248-253.	2.4	10
20	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
21	Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2021, 5, 1187-1195.	2.4	5
22	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
23	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.4	2
24	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 1214-1221.	6.4	14
25	A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	2.8	10
26	Intracellular Signaling. , 2020, , 24-46.e12.		0
27	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020, 38, 406-414.	1.6	60
28	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020, 126, 4532-4544.	4.1	14
29	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 907-915.	1.9	21
30	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320.	3.0	9
31	Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100179.	1.7	4
32	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 387-394.	1.9	32
33	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975.	12.8	37
34	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 977-988.	7.0	104
35	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 809-818.	0.8	23
36	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , 2019, 248, 260-265.	4.5	37

#	ARTICLE	IF	CITATIONS
37	Lessons learned from exceptional responders. Expert Review of Precision Medicine and Drug Development, 2019, 4, 73-80.	0.7	0
38	Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Scientific Reports, 2019, 9, 18882.	3.3	33
39	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. American Journal of Surgical Pathology, 2019, 43, 920-927.	3.7	59
40	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
41	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164
42	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	1.9	104
43	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
44	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. European Urology Focus, 2019, 5, 365-368.	3.1	20
45	Exceptional Responders. , 2019, , 83-97.		0
46	Novel biomarkers in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 115-119.	1.6	5
47	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
48	Molecular Alterations in the Pathogenesis of Bladder Cancer Subtypes and Urothelial Carcinoma Variants. Molecular Pathology Library, 2018, , 65-83.	0.1	0
49	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	2.0	27
50	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e113-e120.	1.9	7
51	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	7.0	85
52	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
53	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	1.6	399
54	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110

#	ARTICLE	IF	CITATIONS
55	Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants. <i>Surgical Pathology Clinics</i> , 2018, 11, 713-723.	1.7	26
56	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
57	Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions. <i>Current Treatment Options in Oncology</i> , 2018, 19, 54.	3.0	16
58	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411
59	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. <i>Oncotarget</i> , 2018, 9, 28702-28716.	1.8	27
60	Editorial Comment. <i>Urology</i> , 2017, 102, 147.	1.0	1
61	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2017, 77, 1035-1046.	0.9	15
62	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
63	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017, 35, 742-750.	2.6	10
64	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nature Communications</i> , 2017, 8, 2193.	12.8	99
65	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <i>PLoS Medicine</i> , 2017, 14, e1002309.	8.4	256
66	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959.	1.9	263
67	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
68	Activating mutation of <i>PDGFRB</i> gene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case report. <i>Oncotarget</i> , 2017, 8, 81709-81716.	1.8	11
69	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. <i>Bladder Cancer</i> , 2016, 2, 203-213.	0.4	3
70	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016, 70, 771-775.	1.9	69
71	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4007.	1.6	147
72	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016, 122, 3715-3723.	4.1	50

#	ARTICLE	IF	CITATIONS
73	Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. <i>Cancer Investigation</i> , 2016, 34, 517-520.	1.3	12
74	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e81-e90.	1.9	4
75	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
76	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.4	36
77	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2015, 67, 198-201.	1.9	122
78	The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience. <i>Oncologist</i> , 2015, 20, 508-515.	3.7	36
79	Targeted Therapy in Advanced Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 253-262.	1.8	14
80	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. <i>BMC Cancer</i> , 2015, 15, 242.	2.6	25
81	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4099-4105.	1.6	88
82	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977.	1.9	202
83	Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. <i>Nature</i> , 2015, 518, 240-244.	27.8	486
84	New Molecular Markers with Diagnostic and Prognostic Values in Bladder Cancer. , 2015, , 235-246.		0
85	Genetic and Epigenetic Alterations in Urothelial Carcinoma. , 2015, , 253-259.		0
86	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	9.4	506
87	Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy. <i>Cancer Discovery</i> , 2014, 4, 1014-1021.	9.4	114
88	Bevacizumab Shows Activity in Patients With Low-Grade Serous Ovarian and Primary Peritoneal Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1010-1014.	2.5	75
89	Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 3712-3720.	7.0	88
90	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3110-3115.	7.1	736

#	ARTICLE	IF	CITATIONS
91	Intracellular Signaling. , 2014, , 22-39.e8.		1
92	Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 303-311.	1.6	55
93	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	1.6	282
94	BRAF Mutation is associated with early stage disease and improved outcome in patients with lowâ€grade serous ovarian cancer. Cancer, 2013, 119, 548-554.	4.1	169
95	Phase <sc>II</sc> study of everolimus in metastatic urothelial cancer. BJU International, 2013, 112, 462-470.	2.5	153
96	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	12.6	681
97	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 1089-1097.	2.3	30
98	Somatic mutation of fibroblast growth factor receptorâ€3 (<i>FGFR3</i>) defines a distinct morphological subtype of highâ€grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	4.5	73
99	CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER. , 2011, , 559-615.		0
100	Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1917-1932.	2.4	16